The estimated Net Worth of Jason Amello is at least $705 Thousand dollars as of 28 February 2020. Mr Amello owns over 6,976 units of Akebia Therapeutics stock worth over $208,284 and over the last 13 years he sold AKBA stock worth over $60,691. In addition, he makes $435,661 as Exec. Officer at Akebia Therapeutics.
Mr has made over 3 trades of the Akebia Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 6,976 units of AKBA stock worth $60,691 on 28 February 2020.
The largest trade he's ever made was selling 6,976 units of Akebia Therapeutics stock on 28 February 2020 worth over $60,691. On average, Mr trades about 544 units every 98 days since 2012. As of 28 February 2020 he still owns at least 144,642 units of Akebia Therapeutics stock.
You can see the complete history of Mr Amello stock trades at the bottom of the page.
Jason A. Amello is the Exec. Officer at Akebia Therapeutics.
As the Exec. Officer of Akebia Therapeutics, the total compensation of Mr Amello at Akebia Therapeutics is $435,661. There are 8 executives at Akebia Therapeutics getting paid more, with John Butler having the highest compensation of $4,316,960.
Mr Amello is 53, he's been the Exec. Officer of Akebia Therapeutics since . There are 9 older and 10 younger executives at Akebia Therapeutics. The oldest executive at Akebia Therapeutics Inc. is Adrian Adams, 69, who is the Independent Chairman of the Board.
Jason's mailing address filed with the SEC is C/O ACER THERAPEUTICS INC., ONE GATEWAY CTR. STE. 356, NEWTON, MA, 02458.
Over the last 11 years, insiders at Akebia Therapeutics have traded over $3,056,393 worth of Akebia Therapeutics stock and bought 2,141,907 units worth $27,915,834 . The most active insiders traders include Holdings A/S Novo, Muneer A Satter, and Mark J Enyedy. On average, Akebia Therapeutics executives and independent directors trade stock every 28 days with the average trade being worth of $43,534. The most recent stock trade was executed by Nicole R. Hadas on 13 May 2024, trading 12,016 units of AKBA stock currently worth $15,140.
akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.
Akebia Therapeutics executives and other stock owners filed with the SEC include: